The study of neurotropic autoantibody levels in patients with epilepsy, Parkinson’s disease and schizophrenia
| Autor: | M. V. Baturina, G. I. Mamtseva, O. I. Boev, V. B. Yarovitsky, E. V. Grudina, V. A. Baturin, O. V. Borodina, V. P. Telbuh, S. N. Rudenko, M. V. Baturin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 4, Pp 33-35 (2018) |
| Druh dokumentu: | article |
| ISSN: | 3034-3062 3034-3453 |
| Popis: | The blood plasma IgG autoantibodies to human protein S-100, to NMDA-receptors and to dopamine receptor type 2 were determined in 13 epilepsy patients with secondary generalized seizures, 16 - in Parkinson patients, 33 - in schizophrenia patients at the age of 18-78. All the enrollees were male. The level of antibodies to S-100 in patients with Parkinson’s was close to normal, it was increased in epilepsy patients and in 59 % of schizophrenia patients. Herewith, in 41 % of schizophrenia patients the levels of autoantibodies to protein S-100 were within normal range. The level of autoantibodies to NMDA-receptors was moderately increased in patients with Parkinson’s and noticeably increased in patients with epilepsy. 45 % of patients with schizophrenia showed a significant increase in NMDA receptor autoantibodies, the others - had normal levels of antibodies. The level of autoantibodies to dopamine receptors in patients with Parkinson’s was normal, and in patients with epilepsy it was significantly increased. In 21 % of patients with schizophrenia the level of autoantibodies to dopamine receptors was normal and in 79 % of patients had significantly increased level of autoantibodies. In patients with schizophrenia high levels of antibodies to dopamine receptors overlapped with high levels of autoantibodies to S-100. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|